- Home
- LNTH
as 02-21-2025 4:00pm EST
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Upcoming Earnings Alert:
Get ready for potential market movements as Lantheus Holdings Inc. LNTH prepares to release earnings report on 26 Feb 2025.
| Founded: | 1956 | Country: | United States |
| Employees: | N/A | City: | NORTH BILLERICA |
| Market Cap: | 6.0B | IPO Year: | 2015 |
| Target Price: | $132.67 | AVG Volume (30 days): | 832.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.02 | EPS Growth: | 304.57 |
| 52 Week Low/High: | $56.44 - $126.89 | Next Earning Date: | 02-26-2025 |
| Revenue: | $1,496,799,000 | Revenue Growth: | 24.15% |
| Revenue Growth (this year): | 19.64% | Revenue Growth (next year): | 5.16% |
Stock Insider Trading Activity of Lantheus Holdings Inc. (LNTH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thrall James H | LNTH | Director | Jan 15 '25 | Sell | $94.76 | 1,000 | $94,760.00 | 33,207 |
Latest Lantheus Holdings Inc. News
LNTH Breaking Stock News: Dive into LNTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 hours ago
Lantheus to Present at Upcoming Investor Conferences
Insider Monkey
a day ago
Is Lantheus Holdings (LNTH) One of the Best Fast Growth Stocks to Buy Right Now?
Zacks Small Cap Research
2 days ago
LNTH: Earnings Report Next Week
Argus Research
3 days ago
LNTH: Raising target price to $88.00
MT Newswires
10 days ago
B. Riley Adjusts Lantheus Holdings Price Target to $127 From $146, Maintains Buy Rating
GlobeNewswire
10 days ago
Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
GlobeNewswire
17 days ago
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
Argus Research
17 days ago
LNTH: What does Argus have to say about LNTH?
Compare LNTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LNTH Lantheus Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.